Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
StoneMoney......I think if you run up to the HDC office in Georgia or across the street from there you might just catch Bill and Barnhill on the golf course. I recall prior that they did live within 2 miles of one another but don't know if they actually play doubles or not?
I hope all are having a super Thanksgiving like so many of us...have a great weekend.
Just in tests alone NeoGenomic has over 624 tests....WHAT DOES HDC have, absolutely NOTHING!
what in the world has HDC ever shown us besides how to run a company into the ground without trying meaning it appears no one has ever been at the helm to really take responsibility except a couple and they apparently got jerked enough So they hit the road. HDC was very lucky that NEO gave them a hand out but what really sucks a big one is HDC must have known even prior to the second one year extended term that NEO was done with them but do you think HDC would stand up and tell us the real deal? ...NOPE as they never have and just looking back on 13 plus years clearly show the truth of what HDC really is and what they are made of. Who knows as I see it HDC just may have also been in breach NOT defending their patent portfolio early enough within the contract between the two who really knows for sure but it seems clear to me that HDC possibly knew when the 2 one year extension ran out that NEO was done with us, PERIOD!
King Oil...I just have to shake my head at the HDC. I can't help but think that HDC thought that somehow that Maher Albitar and our Hong Zang WAS ACTUALLY WORKING FOR US? Go to Freepatents online and check out the patents by them under the NeoGenoic household. Next look at how many tests under the "NeoLab" tm.
I mentioned long ago that NEO only needed our technology for what??? and what? do we offer them (NEO). We offer to "ENHANCE" process....increase efficiency! So during all this it is clear when I read your last post that stage 1 and stage 2 proved the same results 2014 it is now almost 2017 Perhaps it wasn't enough of an increase to warrant all the BS from such an company as HDC or just maybe they did rip HDC off. Actually do you really think HDC really cares. Makes you think great finally they got it stuck up theirs like HD has us all these years. Mind you the company officers probably wrapped themselves in "C" shares so when the crap finally hits the fan they will get paid and us retail peons will still get the shaft. Just look at HDC .. what a joke... it was played on us not them!
NEOLAB™ AML PROFILE - LIQUID BIOPSY
This test is performed by sequencing of select exons of the genes listed using cell-free plasma DNA/RNA. ASXL1, BCOR, BRAF, CEBPA, CSF3R, DNMT3A, E...
NEOLAB™ BTK INHIBITOR ACQUIRED RESISTANCE PANEL - LIQUID BIOPSY
The NeoLAB™ BTK Inhibitor Acquired Resistance Panel is a blood test performed by modified properietary bi-directional sequencing of the BTK and PLC-ga...
NEOLAB™ EGFR T790M - LIQUID BIOPSY
The NeoLAB EGFR T790M - Liquid Biopsy test is a sequencing based assay that can detect the EGFR T790M mutation in plasma with high sensitivity (0.1...
NEOLAB™ FLT3 MUTATION ANALYSIS - LIQUID BIOPSY
Detection of internal tandem duplication and exon 20 tyrosine kinase domain (TKD) mutations using bidirectional sequencing. Positive results identify ...
NEOLAB™ IDH1 MUTATION ANALYSIS - LIQUID BIOPSY
Bi-directional sequencing of the exon 4 mutation hotspot region in the IDH1 gene. Testing is performed on cell-free plasma DNA/RNA to increase sens...
NEOLAB™ IDH2 MUTATION ANALYSIS - LIQUID BIOPSY
Bi-directional sequencing of the exon 4 mutation hotspot region in the IDH2 gene. Testing is performed on cell-free plasma DNA/RNA to increase sensit...
NEOLAB™ INV(16), CBFB-MYH11 TRANSLOCATION - LIQUID BIOPSY
Real-time RT-PCR for quantitative detection of the inv(16) CBFB-MYH11 fusion transcript using cell-free plasma DNA/RNA. This assay identifies type A f...
NEOLAB™ KIT (C-KIT) MUTATION ANALYSIS - LIQUID BIOPSY
Bi-directional sequencing of KIT exons 8, 9, 11, 13 and 17 for detection of activating mutations including the common mutation D816V. Testing is perfo...
NEOLAB™ KRAS MUTATION ANALYSIS - LIQUID BIOPSY
Bi-directional sequencing of exons 2 and 3 of the KRAS gene. High-sensitivity sequencing is used for enhanced detection of mutations in codons 12, 13,...
NEOLAB™ MDS/CMML PROFILE - LIQUID BIOPSY
This test is performed by the sequencing of select exons of the genes listed using cell-free plasma DNA/RNA. ASXL1, BCOR, BCORL1, BRAF, CBL, CEBPA,...
NEOLAB™ MYELOID DISORDERS PROFILE - LIQUID BIOPSY
This test is performed on cell-free DNA/RNA in peripheral blood plasma by sequencing select exons of the genes listed. ABL1, ASXL1, ATRX, BCOR, BCO...
NEOLAB™ NPM1 MUTATION ANALYSIS - LIQUID BIOPSY
PCR and fragment analysis of exon 12 of the NPM1 gene to detect small insertion mutations specific to AML. Positive results are reported quantitativel...
NEOLAB™ NRAS MUTATION ANALYSIS - LIQUID BIOPSY
Bi-directional sequencing of NRAS exons 2 and 3 which includes sites of common activating mutations in codons 12, 13, 59, and 61. Testing is performed...
NEOLAB™ PML-RARA TRANSLOCATION, T(15;17) - LIQUID BIOPSY
Real-time RT-PCR for quantitative detection of the t(15;17) PML-RARA fusion transcript using cell-free plasma DNA/RNA. Both long and short isoforms of...
NEOLAB™ PROSTATE - LIQUID BIOPSY
NeoLAB Prostate is a qRT-PCR test designed to look at expression levels of the genes AR, B2M, ERG, GAPDH, HSPD1, IMPDH2, PCA3, PDLIM5, PSA, PTEN, TMPR...
NEOLAB™ RUNX1-RUNX1T1 (AML1-ETO) TRANSLOCATION, T(8;21) - LIQUID BIOPSY
Real-time RT-PCR for quantitative detection of the t(8;21) RUNX1-RUNX1T1 fusion transcript (formerly called AML1-ETO) using cell-free plasma DNA/RNA.
NEOLAB™ SOLID TUMOR MONITOR - LIQUID BIOPSY
The NeoLAB™ Solid Tumor Monitor is a blood test that uses cell-free circulating tumor DNA (ctDNA) or RNA in combination with next-generation ...
MBMoney...they will file within the next 7 business days but that doesn't change anything for HDC... of course you already know this.
King...I see any movement either way as just typical HDC regardless what is happening in the market or anywhere in the world. I firmly believe we are cooked/done. I don't see NeoGenomic corporation of any abuse involving our patents. I see HDC as the SOS different day with them continuing to place blame on their 100% FAILURES for the past 13 plus years. If any company is looking on how to screw up or destroy any shareholders hope one look at our track record shall be clear to all!
HDC gets the highest score/rating of AAA+ in corporate destruction strategy. Our patents all total would N O T be valued EVEN AT .10 per share...$30 million
My opinion of course!
Page 2 Part D from the Declaration of interference
Part D. Initial conference call
A telephone conference call to discuss the interference is set for 4:00 p.m. on 9 November 2016(the board will set up the call). No later than four business days prior to the conference call, each party shall file and serve a list of motions the party intends to file. A sample schedule taking action during the motion phase appears as Form 2 in the STANDING ORDER. Counsel are encouraged to discuss the schedule prior to the conference call and to agree on dates for taking action. A typical motion period lasts approximately eight(8) months. Counsel should be prepared to justify any request for a shorter or longer period.
re: While those one-year extension terms are complete, the Company and NeoGenomics continue to collaborate on efforts to commercialize the licensed technologies.
_____________________________
In other words HDC must be collaborating with NEO on commercializing EFFORTS to make the product. If NEO answered the phone and said hello that would acknowledge effort by NEO. Maybe NEO told them to take a hike - that would be collaboration too at least the way HDC has always operated.
But all this reality hurts when I try to smile!
HDC wasn't blind sided they decided to close their eyes and try to place blame as usual. (my opinion of course) I mean HDC was lucky to have had any contact with HEO. NeoGenomic corporation just isn't going to mess with a crap-o-la like HDC. Another point is maybe some may not understand that SVM in general does not belong to HDC.
The horrible joke is on 13 plus years for me, Barnhill was well known back in 2000-2003 and I was surprised to see him act as such but I just didn't want to give up hope so I held my stock.
No doubt 99% percent of these pennies never make it but this one should have.
It will be area 2022- 2024 before we really see another really good bubble to get into. We will be having a depressed/depression coming regardless of who could be in office as President. Damn in 2022-24 I may not be around but If I am I'll be playing it.
Damn HDC SUCKS!!
NeoGenomics agreed to use its best efforts to commercialize certain products within one year of the date of the license, subject to two one-year extensions per product if needed, including a “Plasma Prostate Cancer Test”, a “Pancreatic Cancer Test”, a “Colon Cancer Test”, a “Cytogenetic Interpretation System”, and a “Flow Cytometry Interpretation System.” NeoGenomics has completed both of its one-year extension terms of the license. While those one-year extension terms are complete, the Company and NeoGenomics continue to collaborate on efforts to commercialize the licensed technologies.
If NeoGenomics has not generated $5.0 million of net revenue from products, services and sublicensing arrangements by January 2017, we may, at our option, revoke the exclusivity with respect to any one or more of the initial licensed products, subject to certain conditions. The Company does not expect NeoGenomics to generate $5.0 million of net revenue related from products, services and sublicensing arrangements by January 2017.
___________________________
King, let us face the facts HDC was lucky to have had any monies from NeoGenomic. I think HDC has been fraudulent as far as I'm concerned. Just look at the past 13 plus years of HDC history it is clear to me. And as an on going salute to the SOS different day just look at the "SVM Capital" another joke to keep the shares moving in the direction needed. NOPE! I don't blame NEO but clearly HDC just look at BQ when they had the agreement for separation which was another one of HDC BS move.
MBMoney - you are very correct!
It is typical of HDC to do the smoke screen as clearly seen over the past 13 plus years that I have been here.
He was hired July 25,2013, maybe he has completed all he can do or perhaps he is in contrast to HDC's past patent attorney's in California - involving the Intel patent dealings or perhaps tired at age 73 or of spinning his wheels involving HDC.
_________________________________________________
Taken from an earlier filing.............
Henry S. Kaplan is a retired attorney with extensive experience. Specifically, Mr. Kaplan was a patent examiner with the United States Patent and Trademark Office, Chemical Arts, as well as partner and/or shareholder in Dressler Goldsmith et. al.; the Law Office of Henry S. Kaplan, Chicago, Illinois; Miller Ciresi et al, Minneapolis, Minnesota; and Shutts & Bowen, Miami, Florida.
Mr. Kaplan has experience as a principal patent attorney in complex patent and trademark litigation; principal attorney in a number of complex mergers and/or acquisitions; principal counselor for numerous patent and/or trademark license matters. In addition, he has represented a number of public companies as patent and trademark counsel. Mr. Kaplan is a former faculty member of American Law Institute and lecturer for symposiums held by the American Bar Association and the Minnesota Bar.
Mr. Kaplan earned his bachelor degree from the City University of New York in 1963 and his Juris Doctorate from the Washington College of Law at American University in 1967. He is a retired member of the Bar of the State of Illinois and Registered Patent Attorney with the United States Patent and Trademark Office.
King Oil...it appears that 4 of HDC patents that were licensed to NEO may have been walked on by Intel's 7,685,077 patent.
HDC is responsible to enforce and maintain their patents in regarding licensing agreement with NeoGenomic however, What is the present status of any contract or relationship between HDC and NEO? Is it just lip service, smoke and mirrors or what? I believe it would be fair to state that maybe ANY player or possible further development may not happen until HDC straightens out the patent mess that appears to be INTEL'S fault so with that does HDC stand to gain a quick shot financially by Intel in any manner or will Intel drag the patent dispute on for years to come. I mean look how long it took for HDC to get a response from the USPTO.
* Yet Intel is classified as the junior party that must provide the proof so maybe this won't take years to resolve?
Troubling thoughts exist which is nothing new but the creating of the BS committee is my opinion simply because of the SOS but a different day/week/month or year...I means many years.
Getting back to the past contract with NeoGenomic HDC is responsible to enforce any licensed patents to NEO yet it seems as if that contract is dead in the water.
Do you know if the Raging Bull message board is down or out of business?
I see the link didn't work but I'm sure anyone left in this or concerned would have already accessed the USPTO documents regarding HDC and Intel.
King Oil
You can try this to possibly see the USTPO data filing/filed. I haven't looked at this file but have it printed and filed, Now I will look at it.
http://portal.uspto.gov/pair/view/BrowsePdfServlet?objectId=ITLYV1FYRXEAPX4&lang=DINO
re: Intel to possibly pay HDC to drop the case?
I doubt that Intel would even consider the above actions however, HDC may now have a glass half empty or half full? What do we really have to stand on verse Intel? Even if Intel is not able to produce rightful evidence it still places no money in our pockets. Remember it seems the only company running out of time is HDC not NEO nor INTC. The other sad tale is we have NO real products we just have a few patents that "enhance" and that is all. Of course I hope and poke like a few that are still in this mess but we have had nothing going for us for so many years and HDC comes out with that press release about forming a committee. You have been here long enough to know that BQ would love nothing more than to sell this company and cash in ASAP which means an exit FAR less than .20 cents per share, do the math? Our hope was NeoGenomic and I think they are basically done with us but who really knows. I'm still sick about HDC talking about forming a committee as if they were ever able to accomplish anything in the first place.
Well! looks like I was wrong about the USPTO being done with that INTEL patent. As seen below in todays 8-K filing by HDVY. I don't see that changing anything as to our future existence at this point but I was/am wrong in saying that the USPTO was done with HDC in that matter. "My sincere apology" for that comment!!
ITEM 7.01 Regulation FD Disclosure
As previously disclosed, Health Discovery Corporation (the “Company”) submitted a patent application to provoke an interference with Intel’s Patent No. 7,685,077. The application file had been transferred to the U.S. Patent Office’s Interference Division.
On September 21, 2016, the Company received notification that the United States Patent and Trademark Office (“USPTO”) declared an Interference between the Company’s pending patent application covering SVM-Recursive Feature Elimination (“SVM-RFE”) and Intel’s Patent No. 7,685,077, entitled “Recursive Feature Eliminating Method based on a Support Vector Machine”. An Interference is an administrative proceeding within the USPTO that is used to determine which party was the first to invent an invention that is claimed in two (or more) independently-owned patent applications. The Company has been designated the “Senior Party” in the Interference, meaning that it is entitled to a presumption of prior inventorship based on its earlier filing date. As the “Junior Party”, the burden falls upon Intel to prove that it conceived and reduced the claimed invention to practice prior to the Company’s earlier filing date.
In addition to the patent application involved in the Interference, the Company currently has three issued U.S. patents and five issued foreign patents covering the SVM-RFE method.
ITEM 9.01 Financial Statements and Exhibits
(a) Not applicable
(b) Not applicable
(c) Not applicable
(d) Exhibits
None.
https://www.sec.gov/Archives/edgar/data/1141788/000157104916018479/t1600608_8k.htm
I don't know why but I'm actually surprised they had the nerve to even insult us shareholders with a press release as such.
Why not select a committee for when lunch time is to begin? My point in saying this is you can select all day long which is the SOS on a different day where as we need thing to get done and be done not repeating things like taking years and years to have Barnhill removed. I gather I shouldn't get so excited but you guys are just kicking the can don't the road with blinders on.
So you do realize it appears strongly that NEO is done with us and if you think anyone will buy this story about a new committee, well, nonsense will most likely be a response. If NEO can't or won't do anything for HDC what in the world do you think a few directors in HDC can do over the typical long distance calls that are made.
Hey HDC all this reminds me of Laurel and Hardy.
I hope not but maybe NEO is headed in a different direction.
As for intellectual property? we have seen how great our patents have made money for us over the past 13 years and money will be shot in early 2017?
I really now believe that all HDC are doing is licking the can down the road and playing cards with HDC stock and laughing day and night they have nothing to lose especially if they are holding any of those "C" shares.
Hey BQ I gather NEO & SVM Capital have just about done with their belly flopping. Why in the world will you not tell everyone that that HDC will never really do anything about that Intel patent. Maybe because many already know it belongs to Intel and HDC has no rights to that patent.
NeoGenomics License
On January 6, 2012, we entered into a Master License Agreement (the “NeoGenomics License”) with NeoGenomics Laboratories, Inc. (“NeoGenomics Laboratories”), a wholly owned subsidiary of NeoGenomics, Inc. (“NeoGenomics”). Pursuant to the terms of the NeoGenomics License, we granted to NeoGenomics Laboratories and its affiliates an exclusive worldwide license to certain of our patents and know-how to use, develop and sell products in the fields of laboratory testing, molecular diagnostics, clinical pathology, anatomic pathology and digital image analysis (excluding non-pathology-related radiologic and photographic image analysis) relating to the development, marketing production or sale of any “Laboratory Developed Tests” or LDTs or other products used for diagnosing, ruling out, predicting a response to treatment, and/or monitoring treatment of any or all hematopoietic and solid tumor cancers excluding cancers affecting the retina and breast cancer. We retain all rights to in-vitro diagnostic (“IVD”) test kit development.
As I stated in recent days about the IVD kits - if you read the RB message board you can see where BQ reports that the time to develop/market the IVD Kits are years away so why in the world mention how great the IVD Kits were to be. Simple! they had no clue when they first broke the PR a few years back or MORE!
About NEO compensation before payment as I understand it - I will try and find that right now, OH I have 243k shares of HDC rotting away.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=124695276
September 12, 2016 at 07:43 AM EDT
Health Discovery Corporation Forms Development Committee
Health Discovery Corporation (“HDC” or the “Company”), an intellectual property development company using patent protected advanced mathematical techniques for personalized medicine, announced today that its board of directors has formed a special committee designated as the Development Committee. The purpose of this committee will be to identify options and alternatives that may be available to HDC for the development, commercialization and marketing of an In Vitro Diagnostic (“IVD”) test for prostate cancer. In January 2012 HDC entered into an agreement with NeoGenomics, Inc. (NASDAQ:NEO) to develop and commercialize certain Lab Developed Tests (“LDT”) for various cancers including prostate cancer. Under this agreement HDC retained the right to develop and commercialize IVD tests for cancers.
Health Discovery Corporation (“HDC” or the “Company”), an intellectual property development company using patent protected advanced mathematical techniques for personalized medicine, announced today that its board of directors has formed a special committee designated as the Development Committee. The purpose of this committee will be to identify options and alternatives that may be available to HDC for the development, commercialization and marketing of an In Vitro Diagnostic (“IVD”) test for prostate cancer. In January 2012 HDC entered into an agreement with NeoGenomics, Inc. (NASDAQ:NEO) to develop and commercialize certain Lab Developed Tests (“LDT”) for various cancers including prostate cancer. Under this agreement HDC retained the right to develop and commercialize IVD tests for cancers.
Additionally, the committee will consider options to develop and commercialize other elements of its substantial intellectual property portfolio as they relate to medical tests and diagnostic testing methods. HDC believes its technology may be effective for the increasing importance of Next-Generation Sequencing (“NGS”) and other methods relating to the advancement of personalized medicine, including, but not limited to image analysis interpretation software.
The chairman of the Development Committee will be George H. McGovern, III, who joined HDC’s board in May 2016. The Development Committee will report to HDC’s board of directors. Mr. McGovern may be reached at gmcgovern@healthdiscoverycorp.com.
About Health Discovery Corporation
Health Discovery Corporation is an intellectual property development company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools may lead to scientific discovery. Its primary business consists of licensing its intellectual property and developing diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology.
Forward-Looking Statements
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements in relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics, computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.
All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160912005716/en/
Contacts:
Health Discovery Corporation
Kevin Kowbel, CEO, 678-336-5300
investor@healthdiscoverycorp.com
Poof! 400k shares spittoon.eom
King, I had never really thought close enough about the development cost and how that process may happen. I have only read 14 pages of the recent HDC filing but just wonder as the development cost happen it appears HDC is paying as NeoGenomic as services are rendered? I'm sure HDC would make payment on progress in development stages or is there a real problem with something?
Also remember as I said long ago that Intel patent is clearly Intel's not ours HDC fell short in so many means and ways when it came to light. Everyone had blamed HDC Attorney's as being responsible for the patent maintenance etc. My question is simply this and among many other things why did HDC not catch the patent problem when it was developing. Intel change/modified that patent 3 times that I know of and even supersized it! Now if that patent stops HDC dead I have no clue. I mentioned a few years ago if anyone thought that NeoGenomic would try and license the Intel patent but I got no response so who knows?
HDC is TOTALLY responsible to maintain their patents and also kick butt if someone messes with HDC's art work. Who knows what may or may not be holding things up.
Has anyone one that may read this sincerely checked out all the SVM patents that have been granted in the past 4 years. You can even check out Barnhill, remember he has been away from HDC long enough to do it to it in other words who is to say or not if out so called ONCE state of the art patents are just like an old "Model A".
Darn shame if true but what the heck do I know!
Upon execution of the NeoGenomics License, NeoGenomics paid us $1,000,000 in cash and issued to us 1,360,000 shares of NeoGenomic’s common stock, par value $0.001 per share, which had a market value of $1,945,000 using the closing price of $1.43 per share for NeoGenomic’s common stock on the OTC Bulletin Board on January 6, 2012. In addition, the NeoGenomics License provides for milestone payments in cash or stock, based on sublicensing revenue and revenue generated from products and services developed as a result of the NeoGenomics License. Milestone payments will be in increments of $500,000 for every $2,000,000 in United States Generally Accepted Accounting Principles (“GAAP”) revenue recognized by NeoGenomics up to a total of $5,000,000 in potential milestone payments. After $20,000,000 in cumulative GAAP revenue has been recognized by NeoGenomics, we will receive a royalty of (i) 6.5% (subject to adjustment under certain circumstances) on net revenue generated from all Licensed Uses except for the Cytogenetic Interpretation System and the Flow Cytometry Interpretation System and (ii) a royalty of 50% of net revenue (after the recoupment of certain development and commercialization costs) that NeoGenomics derives from any sublicensing arrangements it may put in place for the Cytogenetic Interpretation System and the Flow Cytometry Interpretation System.
Also remember the two one year agreement clause had expired probably over a year ago. I don't follow the dates as close now days. I am here just checking and praying that someday I might escape this on even ground.
If you really want to laugh we were Direct Wireless, Inc back in 2002-3 and the business name and address in Texas still exist, it is active and located at same address, unreal at least someone is making money.
NeoGenomics License
On January 6, 2012, we entered into a Master License Agreement (the “NeoGenomics License”) with NeoGenomics Laboratories, Inc. (“NeoGenomics Laboratories”), a wholly owned subsidiary of NeoGenomics, Inc. (“NeoGenomics”). Pursuant to the terms of the NeoGenomics License, we granted to NeoGenomics Laboratories and its affiliates an exclusive worldwide license to certain of our patents and know-how to use, develop and sell products in the fields of laboratory testing, molecular diagnostics, clinical pathology, anatomic pathology and digital image analysis (excluding non-pathology-related radiologic and photographic image analysis) relating to the development, marketing production or sale of any “Laboratory Developed Tests” or LDTs or other products used for diagnosing, ruling out, predicting a response to treatment, and/or monitoring treatment of any or all hematopoietic and solid tumor cancers excluding cancers affecting the retina and breast cancer. We retain all rights to in-vitro diagnostic (“IVD”) test kit development.
As I stated in recent days about the IVD kits - if you read the RB message board you can see where BQ reports that the time to develop/market the IVD Kits are years away so why in the world mention how great the IVD Kits were to be. Simple! they had no clue when they first broke the PR a few years back or MORE!
About NEO compensation before payment as I understand it - I will try and find that right now, OH I have 243k shares of HDC rotting away.
Absolutely "NOT"!
I hate to clue you in simply because I have waited over 13 plus years for this to evolve and it probably won't ever???????????
HDC will not receive monies until all the development and product costs are replenished. I could find that basic statement in past filings but I really would love to see this finally pay out as we had hoped and poked for years.
Everything is time and how much does one have?
Yes King, I checked that out last night. Price of eggs to keep the store open has gone up. There is nothing to say good except if this could just get a good enough run so I could finally get out from under this entire mess.
I was going to post about 2 weeks ago and said it just isn't worth it. I was going to talk about the kits HDC basically looked forward in producing well as you may know it would cost too much and be man many days/years before it would be worth it...in short look for an exit and don't look back if she comes. Nothing good to say about these people who appear to be running HDC except they will do anything to kick the can down the road without making a real dollar for us retail investors/traders. The past meaning 13 plus years tell the truth about this company and as you know SVM Capital is a joke beyond a joke. The same drama has played out and the SVM seems to be not as good as it was first meant to be.
Just look and study all the old CEO and other officers of HDC and it becomes easy to see.
Will there ever be a day that this rises enough for a few of us to dump this stock for a few coins? I really hope so but just don't see it.
HDC was hope and poke now it is far less, what a freaking nightmare!
He can run his mouth in the other message thread about just about anything can't he?
The truth of your question is if he wanted to he could but he won't and his excuse would be proper, he would just say it isn't a public trading company.
Could he really give us the facts as for the percentages of the pie sure he could but he won't.
They will talk for the next 13 years and that will be about all. If SVMC was really on fire or any huge players were interested we would make some kind of pocket change.
When it comes down to it SVMC is running that show and HDC has ZERO say in any of that realm - pure fact!
Taken from another message board indicating discussions from Bill Quirk
re: How valuable does HDC’s 45% ownership of SVM Capital become over time? I don’t know but I’m pretty sure it will be more than the zero that is now reflected in HDC’s stock price. Will anyone have an interest in buying some or all of HDC’s stake in SVMC now or in the future, and if so, at what price? I don’t know [END}
Hey Bill Quirk Why don't you explain what percentage of the pie that SVMC receives from the Manifold Vector dealings, until we know this fact HVDY 45% of SVMC means absolutely NOTHING!
Joey, love your spirit but don't bother trying to paint HDC charts just isn't there nor mostly anything else however we all hope or some of us that some day this will move enough to set us free. There is nothing better than for BQ to see some type of buyout sale of this company even if NEO were interested which I doubt (do to obvious reasons) so lets deal with a BS buyout. say you have 200k shares of HDC. How many shares of HDC equals 1 share of NEO. Mind you that all we are to NEO is a small enhancement to a existing technology of theirs. As far as HDC having a real product we all still have high hopes but the reality is pretty much slim to none which sucks after being here as long as a few have. I'm sure you are a smart trader and not a sucker so do your thing but don't get sucked in. This company was in self destruction mode for so many years until Barnhill spit it out do to FINALLY existing management including Bill Quirk felt enough heat to make it happen. I mean why not everything was milked already and how wants to look like it was there fault.
I would just love to talk with Scott Tobin to see if I was right about a few things posted long ago. I still see Scott as being the fall guy but would not eat it like they wanted, good going Scott you and they are the ones that really know ; - )
I will try to get something out to you soon but it will be nothing to write home about. Nice to hear from you I just stepped back on an extended vacation since HDC and a few other weren't worth watching. As you know been in this for over 13 years. More to you later but not weeks.
I need to get back with "King Oil" since I have been out of town but looked at your post too. As far as I'm concerned NeoGenomic will not release a strong push before it's time. They will have all their ducks in a row T's crossed and I's dotted. They have the know how to do things correctly.
I am concerned with some of the kids over in yahoo that seem to be incline that our share price will rocket into orbit. In the case of HDC we will collect royalties "AFTER EXPENSES" not when NeoGenomic releases product. We offered them a some patent tools to enhance a product no big deal but as you know it is better than nothing. We will be lucky to ever break even to say the least yet I still have hope and won't give up after 13 years.
_____________________________
King...I will post to you later, I'm dead tired
I read the yearly filing from yesterday and concluded as I mentioned prior, SVM Capital is a joke but still have hope for a NeoGenomic.
I hope all my fellow investors here will celebrate my 13 year anniversary with me next month. It will be the SOS different year. Boy did I sure get hung up in this one, I really thought the way that "Direct Wireless" was coming together just prior Barnhill, talks with people up in NY plus discussions with Braswell that we had something that was able to lift far beyond the telecom days.
People should see where all the old players are today. Braswell is doing fantastic but I think Williams is finally out the Shrimp business or maybe in a nursing home. Direct Wireless actually still exist at the same address where this all started, unreal!
It appears little interest for HDVY stock yet a positive thought about a market maker starting to work the positive side of the trading algorithm.
An algorithm (pronounced AL-go-rith-um) A computer program can be viewed as an elaborate algorithm. In mathematics and computer science, an algorithm means a small procedure that solves a recurrent problem.
The current problem - HDVY - no money, please fix!
Something wrong with this picture????
HDVY
last 5602 trade at .05
bid .034 ask .05
10,000 x 150,000
It seems clear to me that a minimum of 3 entities might split the pie so at MOST SVM Capital could receive 33 percent but truly doubt that much percentage. So since HDC is to obtain 45% of SVM Capital the figures basically are as follows. If the 3 entities combined receive $1 million in profit SVM could make as much as $330,000.00 then HDC would absorb $148,500.00
The kicker negative or positive comes when you look at the following yet we don’t know hardly anything of the internals.
What is the full realm of Manifold Partners?
According to Manifold Partners website as follows
Manifold Vector - The new team is the third at Manifold Partners, which was launched in 2013 by Grail Partners and the Cluster Analysis team from Creighton Capital. In 2014, Dr. Simon Nocera and his team from Lumen Partners joined Manifold to establish a Global Macro Value Team.
http://www.grailpartners.com/ourteam/
http://www.manifoldpartners.com/business-management/
Consider this discussion and opinion.